Validation of the SAMe-TT₂R₂ score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists

Summary

The SAMe-TT₂R₂ score has been proposed to identify patients with non valvular atrial fibrillation (AF) who maintain a high average time in therapeutic range (TTR) on vitamin K antagonists treatment (VKA). This score has been validated in several studies, either monocentric or including very selected populations in a specialised setting. Our objective was to validate this score in a nationwide cohort of AF patients. From November 2013 to March 2014 we included in this study the first 10 patients with AF on VKA consecutively seen in 120 outpatient cardiology clinics in Spain. The SAMe-TT₂R₂ score was calculated for each patient and TTR in the preceding six months was estimated by Rosendaal method. A total of 1,056 patients were recruited (mean age 73.6 ± 9.8 years, 42 % female). Mean value of TTR was 63.8 ± 25.9 % (median 66.8 %, interquartile range 45.6 %-85.4 %). We found a progressive decline in mean TTR from a score of 0 (67.5 % ± 24.6 %) to4 (52.7 ± 28.7 %, p< 0.01). The score was able to discriminate which patients had a good anticoagulation control (TTR65 %) with a C-statistic of 0.57 (95 %CI 0.53–0.60, p< 0.0005). A SAMe-TT₂R₂ score of 0–1 was associated with a good anticoagulation control with a sensitivity, specificity, positive and negative predictive values of 64 %, 48 %, 58 % and 54 %, respectively; and the odds ratio of having a TTR< 65 % if the score was2 was 1.64 (95 % confidence interval 1.33–1.95, p< 0.001). In conclusion, in this nationwide population with AF on VKA, the SAMe-TT₂R₂ score had a significant, although moderate, ability to identify patients with a good anticoagulation control.

Keywords

SAMe-TT₂R₂ score - atrial fibrillation - anticoagulation - time in therapeutic range - validation

• References

• 1 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 2 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
• 3 Ruiz Ortiz M, Romo E, Mesa D. et al. Outcomes and safety of antithrombotic treatment in patients aged 80 years or older with nonvalvular atrial fibrillation. Am J Cardiol 2011; 107: 1489-1493.
• 4 Ruiz Ortiz M, Romo Peñas E, Franco Zapata M. et al. Oral anticoagulation for nonvalvular atrial fibrillation: are scientific recommendations effective and safe in daily clinical practice?. Rev Esp Cardiol 2006; 59: 688-695.
• 5 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
• 6 Cancino RS, Hylek EM, Reisman JI. et al. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thromb Res 2014; 133: 652-656.
• 7 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
• 8 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 9 Le Heuzey JY, Ammentorp B, Darius H. et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833-841.
• 10 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation– developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
• 11 Miller CS, Grandi SM, Shimony A. et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-460.
• 12 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
• 13 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest 2013; 144: 1555-1563.
• 14 Lip GY, Haguenoer K, Saint-Etienne C. et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
• 15 Gallego P, Roldán V, Marin F. et al. SAMe-TT₂R₂ Score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
• 16 Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S. et al. Evaluation of SAMe-TT₂R₂ risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace. 2015 Epub ahead of print.
• 17 Skov J, Bladbjerg EM, Bor MV. et al. SAMe-TT₂R₂ does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014; 145: 187-188.
• 18 Poli D, Antonucci E, Testa S. et al. A prospective validation of the SAMe-TT₂R₂ score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 9: 443-447.
• 19 Anguita-Sánchez M, Bertomeu-Martínez V, Cequier-Fillat A.. on behalf of CALIFA study investigators.. Quality of anticoagulation with vitamin K antagonists in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol. 2015 Epub ahead of print.
• 20 Rosendaal F, Cannegiester S, Van der Meer F. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
• 21 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
• 22 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 23 Ministerio de Sanidad, Servicios Sociales e Igualdad.. Agencia Española de Medicamentos y Productos sanitarios. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales en la prevención del ictus y de la embolia sistémica en pacientes con fibrilación aurícular no valvular. Informe de posicionamiento terapéutico UT/V2/18122012. 19 de Diciembre de 2012.
• 24 Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT₂R₂ score. Eur Heart J Cardiovasc Pharmacother. 2015 Epub ahead of print.
• 25 Fihn SD, Gadisseur AA, Pasterkamp E. et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
• 26 National Institute for Health and Care Excellence.. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180) 2014. http://guidance.nice.org.uk/CG180 .
• 27 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2012; 33: 1500-1510.
• 28 Potpara TS, Polovina MM, Licina MM. et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5: 319-326.
• 29 Van Staa TP, Setakis E, Di Tanna GL. et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39-48.
• 30 Abu-Assi E, Otero-Raviña F, Allut Vidal G. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol 2013; 166: 205-209.
• 31 Roldán V, Marín F, Fernández H. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179-184.
• 32 Apostolakis S, Lane DA, Guo Y. et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861-867.
• 33 Lip GY, Frison L, Halperin JL. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR. Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
• 34 Hess PL, Mirro MJ, Diener HC. et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3–4, 2012. Am Heart J 2014; 168: 239-247.